Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)‘s stock had its “buy” rating restated by Royal Bank Of Canada in a research report issued on Friday. They currently have a $54.00 price target on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 57.89% from the stock’s previous close.

Several other research analysts have also weighed in on PCRX. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. Mizuho reaffirmed a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Pacira Pharmaceuticals in a research note on Tuesday, August 22nd. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $41.00 target price for the company. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Tuesday, October 3rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $44.00 target price (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, October 1st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $52.07.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). The company had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $0.21 EPS.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/13/pacira-pharmaceuticals-inc-pcrx-given-buy-rating-at-royal-bank-of-canada.html.

In related news, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares in the company, valued at approximately $783,216. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,390 shares of company stock worth $1,215,480. 6.60% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its holdings in Pacira Pharmaceuticals by 111.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,051 shares of the company’s stock valued at $104,000 after acquiring an additional 1,607 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after acquiring an additional 1,149 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Pacira Pharmaceuticals in the second quarter valued at approximately $114,000. BlackRock Inc. raised its holdings in Pacira Pharmaceuticals by 122.7% in the first quarter. BlackRock Inc. now owns 2,497 shares of the company’s stock valued at $133,000 after acquiring an additional 1,376 shares in the last quarter. Finally, FNY Partners Fund LP acquired a new stake in Pacira Pharmaceuticals in the first quarter valued at approximately $136,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.